Lymphoma

Researchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…

This study looks at how well a pneumonia vaccine (PCV20) works in people who have recovered from B-cell lymphoma and were treated with anti-CD20 therapy. Researchers want to see if a single dose or a boosted dose is safer and more effective at preventing pneumococcal infections. …

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This study tests a new treatment for children and young adults up to age 30 whose leukemia or lymphoma has come back or not responded to standard therapy. The treatment uses the patient's own immune cells (T cells) that are genetically modified in a lab to recognize and attack ca…

This early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…

This phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the …

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…

This early-phase trial tests an oral drug called TLN-254 in about 50 adults with relapsed or refractory T-cell lymphoma. The main goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug by mouth on a set schedule, and researchers will monitor r…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study tests a modified schedule of standard chemotherapy (R-CHOP) for people aged 75 and older with diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. Twenty-seven p…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…

This early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…

This trial is testing whether adding the experimental drug tazemetostat to the standard R-CHOP chemotherapy regimen can improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL) or high-risk follicular lymphoma. The study has two parts: first, to find…

This study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…

This study tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) works better than standard chemoimmunotherapy for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assi…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…

This phase 2 trial is testing a new combination of drugs, golcadomide and rituximab, in 90 people with newly diagnosed advanced follicular lymphoma. The goal is to see if this combination can improve complete remission rates compared to standard treatments. The study is active bu…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA1 or BRCA2 gene mutation. The drug blocks a protein (WEE1) that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with various adva…

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This phase II trial is testing whether combining two drugs—pembrolizumab, an immunotherapy that helps the immune system attack cancer cells, and entinostat, a drug that may make cancer cells more visible to the immune system—can shrink lymphomas that have come back or stopped res…

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This phase II trial tests the drug trametinib in people whose advanced cancers have specific genetic changes called GNAQ or GNA11 mutations. The drug works by blocking certain proteins that help cancer cells grow. Researchers want to see if trametinib can shrink these tumors or s…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that make cancer cells grow. The trial includes about 10 adults with lymphoma, solid tumors, or multiple myeloma that have not res…

This phase II trial tests the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to multiply. Researchers will measure how many patients' tumors shrink or stop growing f…

This phase II trial is testing the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR mutation and have not responded to standard treatments. Afatinib works by blocking the mutated EGFR protein that helps cancer cells grow. The study ai…

This study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …

This phase 3 trial tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) helps adults with follicular lymphoma that has returned or not responded to previous treatment. Participants receive either the standard therapy alone or …

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…

This phase 3 study tests whether adding the experimental drug golcadomide to standard R-CHOP chemotherapy helps people with untreated high-risk large B-cell lymphoma live longer without their cancer worsening. About 850 adults will be randomly assigned to get either golcadomide o…

This early-stage trial is testing a new drug called valemetostat together with two standard drugs (rituximab and lenalidomide) in 60 adults with follicular lymphoma that has come back or not responded to prior treatment. The main goal is to find a safe dose and check for side eff…

This Phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (non-GCB DLBCL) live longer without their cancer getting worse. About 611 adults aged 18 to 75 who have not been tre…

This phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants…

This study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …

This study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. …

This early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…

This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…

This study tests two drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific genetic change called a BRAF V600 mutation. The goal is to see if these drugs can shrink tumors or stop them from growing. The trial includes 44 participants with various c…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants rec…

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This phase 2 trial tests four different drug combinations in 373 patients aged 60 and older with untreated mantle cell lymphoma. The goal is to see which combination best delays cancer progression. Patients receive rituximab plus bendamustine, with or without bortezomib, followed…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This phase 2 trial tests the drug ipatasertib in 35 adults with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific AKT gene mutation. Ipatasertib is an AKT inhibitor designed to block cancer growth signals. The main goal is to see if the drug can …

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This phase II trial tests the drug crizotinib in 20 adults with advanced or hard-to-treat cancers that have a specific genetic change called MET exon 14 deletion. Crizotinib is a pill that blocks signals cancer cells need to grow. The study aims to see if the drug can shrink tumo…

This phase II trial tests a drug called copanlisib in 35 patients with advanced cancers that have a specific mutation in the PTEN gene. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or slow the disease. The study is small …

This phase 2 trial tests the drug vismodegib in 34 patients with advanced solid tumors, lymphoma, or multiple myeloma that have specific mutations in the SMO or PTCH1 genes. Vismodegib works by blocking a protein involved in cell growth. The main goal is to see if the drug can sh…

This study was designed to test a new treatment called BAFFR CAR-T for people with B-cell blood cancers that came back or didn't respond to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. However, the trial was withdrawn before en…

This phase II trial tests a drug called GSK2636771 in 24 patients whose advanced cancers have a PTEN mutation or deletion. The drug blocks a protein (PI3K-beta) that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing.

This phase II trial tests a drug called GSK2636771 in 35 patients whose cancers have lost a protein called PTEN. The drug blocks a growth signal that these cancers may rely on. Researchers hope to see if it can shrink tumors or stop them from growing.

This study tests a new drug called pirtobrutinib against other approved drugs for mantle cell lymphoma, a type of blood cancer. About 500 people who have already had at least one prior treatment will take part. The goal is to see if the new drug works better at controlling the di…

This pilot study tests whether high doses of a radioactive sugar (FDG) can safely treat advanced cancers that no longer respond to standard therapies. FDG is taken up by cancer cells because they use a lot of glucose, and the radiation may kill them. The study involves 30 adults …

This study tests a drug called ulixertinib in people with advanced cancers that have specific changes in the BRAF gene (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that ha…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if tumors shrink or stop growing, and track how long patients live or stay …

This phase II trial tests the drug MLN0128 (TAK-228) in 35 patients with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific genetic change called an mTOR mutation. The drug works by blocking enzymes that cancer cells need to grow. Researchers will…

This study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team interv…

This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors o…

This phase 2 trial tests the drug crizotinib in patients with advanced cancers (other than lung cancer) that have a specific genetic change called ALK rearrangement. Crizotinib works by blocking the ALK protein, which may stop cancer cells from growing. The study enrolled only 5 …

This phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose …

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …

This phase II trial is testing the drug defactinib in 35 patients whose advanced cancers have a specific genetic change called an NF2 mutation. The drug works by blocking a protein that may help these cancer cells grow. Researchers want to see if defactinib can shrink tumors or s…

This study was designed to test a new treatment called CD30-targeted CAR-T cells for people with lymphoma (a type of blood cancer) that had returned or stopped responding to standard therapy. The treatment involved taking a patient's own immune cells, engineering them to recogniz…

This phase 2 trial tests capivasertib (AZD5363) in 35 patients with advanced cancers that have an AKT mutation. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing.

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced…

This phase II trial tests the drug taselisib in 70 patients with advanced cancers (excluding breast cancer) that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if taselisib can sh…

This study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …

This phase 2 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) improves outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 450 participants will receive one cycle of R-CHOP, then two-thirds will get five more…

This study tests whether a new drug combination (loncastuximab tesirine plus rituximab) works better than standard chemotherapy for adults with diffuse large B-cell lymphoma that has returned or not improved after initial treatment. About 440 participants will be randomly assigne…

This early-phase study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or is not responding to current treatments. The main goals are to find a safe dose and see how the drug works in the body. The study also che…

This phase 3 study compares a new oral drug called pirtobrutinib (LOXO-305) against two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in 238 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been t…

This study tests whether giving radiation and chemotherapy at the same time can better control stage I or II nasal NK cell lymphoma. About 26 newly diagnosed adults are receiving this combination to see if it improves how long the disease stays away. The goal is to manage the can…

This study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…

This study was designed to test whether adding the drug tazemetostat to standard CHOP chemotherapy could improve outcomes for people with certain types of T-cell lymphoma. The trial was withdrawn before enrolling any participants, so no results are available. It would have includ…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This early-phase study tests a new treatment called FT819 for people with B-cell cancers (lymphoma, CLL, or B-ALL) that have not responded to standard therapies. The goal is to find a safe dose and see if the therapy can shrink tumors. About 54 participants will receive FT819 alo…

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This phase 2 trial is testing the drug crizotinib in 44 patients with advanced solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib works by blocking enzymes that help cancer cells grow and spread. The main goal is t…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…

This early-phase study tests a new way to calculate the dose of the chemotherapy drug melphalan for lymphoma patients about to receive a stem cell transplant. Instead of a fixed dose based on height and weight, researchers use a model that considers how previous patients processe…

This phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …

This phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce an…

This study tests a new type of CAR T cell therapy, called ALLO-501A, made from donor cells (not the patient's own). It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or not responded to other treatments. The …

This study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing tha…

This phase 2 trial tests whether adding a stem cell transplant to standard chemotherapy helps people with newly diagnosed primary CNS B-cell lymphoma live longer without their cancer returning. About 113 patients will receive either high-dose chemo plus a stem cell transplant or …

This study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have returned or not responded to treatment. The drug works by blocking an enzyme that cancer cells need to grow. The trial aims to find the safest dose and see if the drug c…

This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested …

This early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participan…

This phase 2 study tests a new drug called sonrotoclax, either alone or combined with zanubrutinib, in 114 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the treatment can shrink tumors and control the disease. Participants include those who…

This study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma. The drugs work together to help the immune system find and kill cancer cells. The goal is to see how many patients achieve a complete response, meanin…

This early-phase study tests a new type of immunotherapy for children and young adults with leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize two different targets (CD19 and CD22) on leukemia cells, t…

This study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…

This early-phase study tests a combination of three drugs (rituximab, bendamustine, and melphalan) followed by a stem cell transplant using the patient's own cells. The goal is to see if this approach is safe and has fewer side effects than standard treatments for older adults wi…

This early-phase trial tests whether adding N-Acetylcysteine (N-AC), an antioxidant, to standard CAR T-cell therapy (Yescarta) is safe for people with lymphoma. Nine participants receive different doses of N-AC to find the highest dose with few side effects. The goal is to see if…

This study tests a stem cell transplant method that removes certain immune cells (T and B cells) from donated stem cells before giving them to patients with blood cancers like leukemia or lymphoma. The goal is to help the new cells grow (engraft) while reducing the risk of graft-…

This early-phase trial tests whether specially trained immune cells (T cells) that are made resistant to a tumor's defense chemical can safely fight relapsed EBV-positive lymphoma. Eight patients will receive two injections of these modified cells, 14 days apart, at increasing do…

This study tests a new type of immune therapy for people with certain blood cancers (CLL, lymphoma, or multiple myeloma) that have come back or not responded to treatment. Researchers take a patient's own T cells, add a special receptor that targets a protein called kappa on canc…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning pat…

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …

This study tests a drug called sonrotoclax (BGB-11417) in 125 people with mantle cell lymphoma that has relapsed or not responded to prior treatments. The trial has two parts: first to find the safest dose, then to see how well it shrinks tumors. Participants take the drug by mou…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This early study tests a new radioactive drug called [18F] Fluoroglutamine, which is designed to be used with PET scanners. Researchers want to see how long it stays in the blood and where it goes in the body, especially whether it collects in tumors. 67 adults with solid cancers…

This study tests whether a probiotic called Lactobacillus plantarum can prevent a serious complication called graft-versus-host disease (GvHD) in the gut of children receiving a donor stem cell transplant. About 173 children with blood cancers or other conditions are taking the p…

This study tests whether a meditation-based mind-body program can improve quality of life for adolescents and young adults (ages 18-39) recently diagnosed with lymphoma. Participants practice guided meditation and mindfulness techniques to help lower distress, anxiety, and depres…

Researchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…

This study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…

This pilot study explores whether chaplain-led compassion meditation can improve spiritual care for patients about to undergo stem cell transplantation for lymphoma or multiple myeloma. Half of the participants will receive these meditation sessions, while the other half gets sta…

This study looks at whether a daily mindfulness app called Headspace can help adults who survived childhood cancer cope with stress. Fifty survivors will use the app for 30 days and wear a wrist device to track stress signs. The main goal is to see if people find the app acceptab…

This study tests a highly precise radiation system (CT-on-Rails or Trilogy) to treat spine tumors that have spread from other cancers. About 150 participants will receive three radiation sessions over two weeks. Researchers will track pain relief and side effects using patient qu…

This study tests whether a single high dose of psilocybin (the active ingredient in magic mushrooms) combined with specialized talk therapy can help people with advanced cancer feel less anxious and more at peace. Fifteen adults with stage IV cancer will receive the treatment and…

This study looks at whether cognitive behavioral therapy (CBT) can help adults with acute myeloid leukemia or lymphoma who feel very tired from their cancer or treatment. Participants will attend up to 7 counseling sessions to learn skills to cope with fatigue, anxiety, and depre…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study tests a program that lets cancer patients receive care at home while undergoing chemotherapy or radiation. It includes remote monitoring and home visits to reduce the need for hospital stays or emergency room visits. The goal is to see if this approach improves quality…

This study tests a communication program for people with advanced cancer and their caregivers. The goal is to help them manage difficult emotions and talk about the patient's illness and treatment wishes. About 45 participants will take part, and the program is tailored for Latin…

This study tests whether a shorter course of radiation (over 2-3 weeks instead of the usual 5-6 weeks) is safe for people with Hodgkin or Non-Hodgkin lymphoma that has returned or not responded to treatment. About 30 participants will receive different radiation doses to find the…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study is creating a large registry of 800 lymphoma patients in Malawi to collect detailed information about the disease. Researchers will perform biopsies and track patients over time to understand how lymphoma affects people in sub-Saharan Africa. The goal is to gather data…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this me…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see…

This study looks at whether a new genomic test called the Molecular Functional (MF) Portrait can quickly provide useful information for treating lymphoma. Researchers will use tumor tissue already collected from 111 adults with diffuse large B-cell lymphoma to see if test results…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study is testing whether a specially designed video game can help young people (ages 15-39) who have had a stem cell transplant for leukemia or lymphoma improve their health habits. Researchers will gather feedback from 40 participants to see if the game is easy and enjoyabl…

This study compares a new total-body PET/CT scanner (uEXPLORER) with a conventional PET/CT scanner in 180 adults with lung cancer, lymphoma, or melanoma. Each participant gets scanned on both machines to see if the new scanner can produce equally good images in a shorter time. Th…

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at the biology of B-cell lymphoma in children and teens to better understand the disease and long-term effects of treatment. About 128 participants will provide tumor and blood samples for genetic analysis. The goal is not to test a new drug, but to gather knowle…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related disorders. The samples are stored in a tissue bank for future research to understand what causes these cancers, how they pr…

This study tracks over 1,400 breast cancer and lymphoma patients to see how chemotherapy affects memory, attention, and thinking skills. Researchers test patients before, right after, and up to years after treatment. The goal is to learn who is most at risk for 'chemo brain' and …

This study tests a decision aid website called Pathways to Fertility for women newly diagnosed with cancer who may face infertility from treatment. About 130 women will use the website or receive standard care to see if it helps them make more informed and less conflicted decisio…

This study follows 69 people infected with HTLV-1, some of whom have developed a rare blood cancer called adult T-cell leukemia/lymphoma. Researchers will track survival rates over 2 and 5 years, along with viral levels and genetic markers. The goal is to better understand how th…

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…

This study examines stored lymph node samples from 100 people in Botswana who had lymphoma between 2012 and 2017. Researchers want to see how often Epstein-Barr virus (EBV) is found in these samples, and whether HIV infection makes a difference. The goal is to better understand t…

This early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…

This study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…

This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…

This study collects blood and tissue samples from people receiving or donating bone marrow transplants for leukemia, lymphoma, or other blood diseases. Researchers will analyze these samples to find genes and proteins linked to cancer development and transplant complications. The…

This study aimed to see if changing how cancer patients think about their illness could improve their quality of life and treatment outcomes. Researchers planned to follow newly diagnosed patients and give some a short mindset training. However, the study was withdrawn before any…